Richmond Pharmacology

Clinical Research News


16 June 2017

DIA, Chicago 2017

Richmond Pharmacology’s Principal Investigators Dr Taubel and Dr Lorch will be presenting at DIA 2017,Chicago.

Join our CEO Dr Jorg Taubel, who will be presenting on the topic ‘Combined Adaptive Early Phase Trials: From First-Time-in-Human to Proof of Concept in One Protocol’ Tuesday AM – 20th of June.

View event details

28 April 2017

Richmond Pharmacology's New London Bridge unit offers unrivalled access to patient recruitment 

Richmond Pharmacology has been settling into life in its New London Bridge Research Unit. The new MHRA accredited unit has been actively running trials in its new surroundings since March 25th with excellent on-going patient feedback. 

View news article

31 March 2017

New CRO unit facility welcomes first overnight patients

One month on from Richmond's opening event, which saw leading industry bodies and stakeholders convene, the CRO has been busy settling in their first patients at the new London Bridge site.

View news article

20 March 2017

Richmond Pharmacology is attending the American Society for Clinical Pharmacology and Therapeutics (ASCPT) event in Washington DC over the next few days.

The event takes place in the Washington Marriott Wardman Park, 15th – 18th March. Dr Jorg Taubel will be presenting his latest scientific poster presentation – The Power of Proving QTc Assay Sensitivity: Moxifloxacin Vs Food and Using The Food Effect to Show Assay Sensitivity: Estimation of Power Using Subsampling Simulations. 

View event details and program

3rd March 2017

Richmond Pharmacology Opens New London Bridge Site

This decision marks the next step in Richmond Pharmacology’s continued growth, having already conducted over 300 studies in London since 2001, often in rare disease areas such as amyloidosis. 

Dr Jorg Taubel, CEO of Richmond Pharmacology commented saying: "The opening of our new research facility is a sign of our continued commitment to working alongside the leading research hospitals and universities in the UK to deliver cutting-edge clinical research across vital disease areas...

View news article

11th November 2016

Accelerated Early Phase Drug Development in the UK and Europe

Tokyo, Japan | 29th November 2016 – Hear the latest updates about how early phase studies can be accelerated globally by starting first in human trials in the UK then rapidly progress into Europe. This will give you access to a population of 500 million people. Speakers include Dr Jorg TaubelDr Ulrike Lorch and Keith Berelowitz (Richmond Pharmacology) , Dr Martin Kane(MRHA), Prof. Dr. Frank-Dietrich Wagner (Charité) and Dr Yukihisa Namiki (DIT).

This year’s meeting is focused on Accelerated Early Phase Drug Development in the UK and Europe.

View press release

21st September 2016

Inotrem successfully completes its first phase I clinical trial with Motrem™, a TREM-1 pathway modulator for the treatment of septic shock

Paris, France, September 13, 2016 – Inotrem SA, a biotechnology company specializing in the control of acute inflammatory syndromes, such as septic shock, announced today the successful completion of the first clinical trial of Motrem in healthy volunteers. 

The principal objective of this first in-man phase I clinical trial, conducted on a double-blind, randomized, placebo-controlled basis, was to evaluate Motrem’s safety, tolerance and pharmacokinetics.

View press release

21st September 2016

Futura Medical plc announce headline results from its efficacy study of the Company's novel gel for the treatment of erectile dysfunction

The study comprised a total of 232 randomised males and it measured, as its primary endpoint, improvement in the erectile function ("EF") domain score of the International Index of Erectile Function ("IIEF"), the scoring system used for the approval of PDE5 inhibitors such as Viagra®. The study was of a placebo-controlled, double blind, home use, crossover design.

View news article

23 March 2016

Access 500 million patients.
Regulators, sponsors and investigators
talk about running clinical trials in the EU.
British Consulate Boston, Cambridge, MA, USA, 24 February 2016

Organised by the British Consulate Boston; the Medicines and Healthcare products Regulatory Agency (MHRA), sponsors and investigators came together for the Clinical Trials in the EU Workshop in Boston last month to discuss how pragmatic regulators, innovative study design and the harmonisation of clinical trials approvals across Europe can help drive early stage clinical programs forward and maximize information obtained. 

Summaries of presentations

Dr Ulrike Lorch Dr Ulrike Lorch
Richmond Pharmacology

Combined adaptive protocols
from First Time in Human to Proof of Concept

Early phase trials aim to explore safety and efficacy and to establish proof of concept in patients as soon as possible. Combined adaptive protocols can accelerate this by encompassing several conventional trials in one single protocol. Single ascending, multiple ascending, food effect, drug-drug-interaction and age/gender comparison parts can be combined. Elements to add value to a trial and to de-risk further drug development can be included. Value can be added by inclusion of Japanese participants, assessing safety, tolerability, pharmacokinetics and pharmacodynamics. Intensive cardiac safety assessments de-risk further drug development. The inclusion of biomarkers and the exploratory evaluation of efficacy in patients may do both, add value and de-risk... Read More »

Read all speaker summaries »

24th Februray 2016

No Triumph Without Trials

The Fight Against Cancer In the last 70 years, the development of clinical cancer research has been remarkable. From the discovery of the first form of effective chemotherapy in 1949 to the genetically tailored cancer drugs of the 90s, treatment methods have evolved dramatically in the modern era thanks to decades of rigorous clinical trials.

With the help of some of the world’s leading oncologists and cancer treatment specialists we’ve decided to produce a timeline which outlines 10 of the most important advances in clinical cancer research...
Read more »

No Triumph Without Trials
View timeline »

8th February 2016

Efficient recruitment in one place 

Richmond Pharmacology is recognised globally by sponsors and CROs alike for its competence in patient recruitment.

10 for the price of 1 
We have the capacity to replace multiple sites confirmed by our rapid and on-time recruitment.

The power of foresight
Our recruitment database of over 200,000 healthy and patient trial seekers provides in depth insight into study feasibility for streamlined study designs, saving both time and cost.


Richmond Pharmacology's people have extensive knowledge and expertise.




View our latest

View Publications Publications



Learn more about Richmond
Pharmacology by viewing
some of our videos

Watch VideosVideos
© 2017 Richmond Pharmacology  |  disclaimer  |  Corporate Accounts  |  site map
Paid Clinical Trials